letaplimab (IBI188) / Innovent Biologics 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  letaplimab (IBI188) / Innovent Biologics
    Enrollment change, Trial completion date, Trial suspension, Trial primary completion date, Combination therapy:  Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS (clinicaltrials.gov) -  Feb 16, 2023   
    P1,  N=120, Suspended, 
    N=126 --> 222 | Trial completion date: May 2022 --> Jun 2024 | Recruiting --> Suspended | Trial primary completion date: Apr 2021 --> Jun 2023 N=12 --> 120 | Trial completion date: Feb 2022 --> Aug 2024 | Recruiting --> Suspended | Trial primary completion date: Dec 2021 --> Dec 2023
  • ||||||||||  letaplimab (IBI188) / Innovent Biologics
    Enrollment change, Trial completion date, Trial termination, Combination therapy, Metastases:  IBI188 Combination Therapy in Solid Tumors (clinicaltrials.gov) -  Oct 4, 2022   
    P1,  N=9, Terminated, 
    IBI188 in combination with azacitidine demonstrated promising efficacy, and a manageable safety profile as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome. N=120 --> 9 | Trial completion date: Oct 2022 --> Jul 2022 | Recruiting --> Terminated; No signs of efficacy in solid tumors
  • ||||||||||  letaplimab (IBI188) / Innovent Biologics
    Trial completion, Trial primary completion date, Metastases:  A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies (clinicaltrials.gov) -  Apr 7, 2022   
    P1,  N=49, Completed, 
    N=120 --> 9 | Trial completion date: Oct 2022 --> Jul 2022 | Recruiting --> Terminated; No signs of efficacy in solid tumors Active, not recruiting --> Completed | Trial primary completion date: Nov 2021 --> Feb 2022
  • ||||||||||  azacitidine / Generic mfg.
    Journal, IO biomarker:  Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody. (Pubmed Central) -  Feb 8, 2022   
    Notably, IBI188 treatment increased vascular endothelial growth factor-A (VEGF-A) levels in a solid tumor model, and combined treatment with an anti-VEGF-A antibody and IBI188 resulted in an enhanced anti-tumor effect. These data indicate that IBI188 is a therapeutic anti-CD47 antibody with anti-tumor potency, which can be enhanced when used in combination with standard-of-care drugs for cancer treatment.
  • ||||||||||  letaplimab (IBI188) / Innovent Biologics
    Suppression of Extracellular Vesicle CD47 Induces Systemic Anti-DLBCL Immunity (GWCC - Hall A1) -  Nov 5, 2021 - Abstract #ASH2021ASH_2207;    
    P1b/2
    Anti-CD47 antibody (IBI188) has shown promise in treating tumors, including Diffuse large B cell lymphoma (DLBCL)...Moreover, high levels of circulating EV CD47 would follow and correlate positively with the phagocytic activity of macrophages, and reflect the presence of a successful anti-tumor immunity elicited by the anti-CD47 therapy. Together, these findings show that EV CD47 represents an unexplored therapeutic target, which could overcome resistance to current CD47 antibody approaches.
  • ||||||||||  letaplimab (IBI188) / Innovent Biologics
    Enrollment closed, Enrollment change, Trial primary completion date, Metastases:  A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies (clinicaltrials.gov) -  Jul 21, 2021   
    P1,  N=49, Active, not recruiting, 
    Together, these findings show that EV CD47 represents an unexplored therapeutic target, which could overcome resistance to current CD47 antibody approaches. Recruiting --> Active, not recruiting | N=92 --> 49 | Trial primary completion date: Jul 2020 --> Nov 2021
  • ||||||||||  letaplimab (IBI188) / Innovent Biologics
    Enrollment open, Combination therapy, Metastases:  IBI188 Combination Therapy in Solid Tumors (clinicaltrials.gov) -  Jul 20, 2021   
    P1,  N=120, Recruiting, 
    Recruiting --> Active, not recruiting | N=92 --> 49 | Trial primary completion date: Jul 2020 --> Nov 2021 Not yet recruiting --> Recruiting
  • ||||||||||  letaplimab (IBI188) / Innovent Biologics
    New P1 trial, Combination therapy, Metastases:  IBI188 Combination Therapy in Solid Tumors (clinicaltrials.gov) -  Apr 26, 2021   
    P1,  N=120, Not yet recruiting,